Judge: Michael Shultz, Case: 22STCV12268, Date: 2022-10-03 Tentative Ruling

INSTRUCTIONS: If the parties wish to submit on the tentative ruling and avoid a court appearance on the matter, the moving party must:

1. Contact the opposing party and all other parties who have appeared in the action and confirm that each will submit on the tentative ruling.

2. No later than 4:00 p.m. on the court day before the hearing, call the Courtroom (310-761-4302) advising that all parties will submit on the tentative ruling and waive hearing; and

3. Serve notice of the Court's ruling on all parties entitled to receive service.

If this procedure is followed, when the case is called the Court will enter its ruling on the motion in accordance with its tentative ruling. If any party declines to submit on the tentative ruling, then no telephone call is necessary, and all parties should appear at the hearing. If there is neither a telephone call nor an appearance, then the matter may either be taken off calendar or ruled on. 

TENTATIVE RULINGS -- http://www.lacourt.org/tentativeRulingNet/ui/main.aspx?casetype=civil




Case Number: 22STCV12268    Hearing Date: October 3, 2022    Dept: A

22STCV12268 Alberto Siordia v. Zoll Medical Corporation

Monday, October 3, 2022 at 8:30 a.m.

 

[TENTATIVE] ORDER SUSTAINING DEMURRER TO PLAINTIFF’S COMPLAINT WITH LEAVE TO AMEND

 

I.            BACKGROUND

The complaint, filed on April 12, 2022, alleges claims for general negligence and products liability arising from Plaintiff’s use of a product made by Defendant, a LifeVest® 4000 (“LifeVest”) which was prescribed by Plaintiff’s doctor. Plaintiff alleges the LifeVest released a shock or jolt due to a defective condition.

 

II.            ARGUMENTS

A.     
Demurrer filed  June 13, 2022

 

Defendant argues that Plaintiff’s claims are pre-empted by federal law unless Plaintiff can allege a parallel state claim. Plaintiff has not alleged that the medical device at issue, which is preapproved by the Federal Drug Administration (“FDA”), violated Federal Food, Drug, and Cosmetic Act (“FDCA”) that would give rise to recovery under state law even in the absence of the FDCA. The allegation alone that the device was defective is insufficient to allege the claims.

B.     
Opposition filed September 28, 2022

  Plaintiff argues that leave to amend is required to conduct discovery and assert valid state claims that are not preempted. Plaintiff cites to federal cases examining parallel state law claims in Florida and Tennessee to determine whether the alleged claims were preempted. There is an established framework for determining whether state claims are preempted by federal law, and Plaintiff has the right to “search for parallel state claims that would effectively avoid preemption.” Opp., 8:2-3. Plaintiff concedes that the complaint is vague but asserts that it is vague because Plaintiff has not conducted any discovery. Opp. 8:3-4.  

C.      Reply filed on September 6, 2022

Defendant argues that contrary to Plaintiff’s opposition, Defendant is not asking for complete immunity from state claims. Plaintiff’s recitation to other case law around the country does not address the Plaintiff’s failure to allege a violation of federal law that also gives rise to recovery under California law. Without an allegation that Defendant violated a parallel state law, Plaintiff’s claims are pre-empted.

 

III.            LEGAL STANDARDS

A demurrer tests the sufficiency of a complaint as a matter of law and raises only questions of law. Schmidt v. Foundation Health (1995) 35 Cal.App.4th 1702, 1706. In testing the sufficiency of the complaint, the court must assume the truth of (1) the properly pleaded factual allegations; (2) facts that can be reasonably inferred from those expressly pleaded; and (3) judicially noticed matters. Blank v. Kirwan (1985) 39 Cal.3d 311, 318.

The court may not consider contentions, deductions, or conclusions of fact or law. Moore v. Conliffe (1994) 7 Cal.4th 634, 638. Because a demurrer tests the legal sufficiency of a complaint, the plaintiff must show that the complaint alleges facts sufficient to establish every element of each cause of action. Rakestraw v. California Physicians Service (2000) 81 Cal.App.4th 39, 43. Where the complaint fails to state facts sufficient to constitute a cause of action, courts should sustain the demurrer. Code Civ. Proc., § 430.10(e); Zelig v. County of Los Angeles (2002) 27 Cal.4th 1112, 1126.

Sufficient facts are the essential facts of the case "with reasonable precision and with particularity sufficiently specific to acquaint the defendant with the nature, source, and extent of his cause of action.” Gressley v. Williams (1961) 193 Cal.App.2d 636, 643-644. Whether the Plaintiff will be able to prove the pleaded facts is irrelevant. Stevens v. Superior Court (1986) 180 Cal.App.3d 605, 609–610.

A demurrer may also be sustained if a complaint is “uncertain.” Uncertainty exists where a complaint’s factual allegations are so confusing, they do not sufficiently apprise a defendant of the issues it is being asked to meet. Williams v. Beechnut Nutrition Corp. (1986) 185 Cal.App.3d 135, 139, fn. 2; Code Civ. Proc., § 430.10(f).

A pleading is required to assert general allegations of ultimate fact. Evidentiary facts are not required. Quelimane Co. v. Stewart Title Guaranty Co. (1998) 19 Cal. 4th 26, 47; Lim v. The.TV Corp. Internat. (2002) 99 Cal. App. 4th 684, 690. However, unlike federal courts, California state courts are not a notice pleading jurisdiction, and notice alone is not a sufficient basis for any pleading. California is a fact pleading jurisdiction. Merely putting an opposing party on notice is not sufficient. Bach v. County of Butte (1983) 147 Cal.App.3d 554, 561; see Diodes, Inc. v. Franzen (1968) 260 Cal.App.2d 244, 250.

Defense counsel met and conferred with Plaintiff’s counsel about the purported defects in the complaint without resolution. Demurrer, 2:1-4, Code Civ. Proc., § 430.41.

 

IV.            DISCUSSION

The court takes judicial notice of the Premarket Approval Plan for the LifeVest issued by the U.S. Food and Drug Administration. RJN, Ex. A. The FDA approved the vest on December 18, 2001. RJN Ex. B. Evid. Code, § 452(c) and (h). https://www.accessdata.fda.gov/ cdrh_docs/pdf/P010030A.pdf.

Pursuant to the Medical Device Amendments of 1976 (“MDA”), "[e]xcept as provided in subsection (b), no State or political subdivision of a State may establish or continue in effect with respect to a device intended for human use any requirement--

(1) which is different from, or in addition to, any requirement applicable under this chapter to the device, and

(2) which relates to the safety or effectiveness of the device or to any other matter included in a requirement applicable to the device under this chapter." 21 U.S.C.A. § 360k (West).

The complaint here alleges state-law claims for products liability and negligence arising from the LifeVest’s unsafe condition, particularly for a manufacturing and design defect, breach of implied warranty, and for failure to warn. Complaint, attachment L-1, .pdf page 7.

To determine whether preemption applies, the court first considers whether the Federal Government has established requirements applicable to the LifeVest, and whether the state-law claims are “different from, or in addition to,” the federal requirements relating to safety and effectiveness, and therefore expressly preempted. Riegel v. Medtronic, Inc. (2008) 552 U.S. 312, 322. The FDA granted premarket approval of the use of the LifeVest subject to conditions. Defendant’s RJN, Ex. B. Among other things, the FDA required Defendant to submit annual, post-approval reports as a condition of continued approval. RJN, Ex. B, .pdf page 27, 29. Therefore, Defendant has satisfied the first prong for express preemption.

The second prong requires a determination of whether the misconduct violates a parallel state law claim as the "failure to plead parallel federal and state law violations with regard to manufacturing defects is fatal” to Plaintiff’s state law claims. De La Paz v. Bayer Healthcare LLC (N.D. Cal. 2016) 159 F.Supp.3d 1085, 1097 [Plaintiff’s failure to allege a breach of any parallel state law duties that could escape preemption warranted dismissal]. Here, the complaint does not allege facts identifying any parallel state law necessary to survive preemption. 

The complaint alleges that the vest or its component parts did not provide adequate warnings of certain dangers associated with the use of the vest. Complaint, attachment, L-1 ¶ (ii). Under De La Paz “a claim based on the failure to warn the FDA of adverse events is not preempted to the extent state tort law recognizes a parallel duty (although a claim based on a failure to warn physicians or patients of adverse events would be preempted).” Stengel, 704 F.3d at 1234. De La Paz at 1096-1097.

The complaint in unclear.  It does not state whether Plaintiff is suing for failure to warn the FDA or failure to warn consumers or physicians. Accordingly, the claim based on a failure to warn is uncertain. Finally, the claims for breach of express and implied warranty are also fatally defective unless Plaintiff alleges parallel federal and state law violations to avoid preemption. De La Paz at 1097.

Plaintiff’s assertion that the complaint is vague because Plaintiff has not conducted any discovery is unpersuasive. Plaintiff has not stated a cognizable claim in the first instance. Plaintiff must research the law to determine whether California has parallel claims for manufacturing defect, failure to warn, and breach of express/implied warranty.

V. CONCLUSION

Plaintiff concedes that the complaint does not allege facts to avoid preemption. The foregoing authority establishes a narrow basis for avoiding federal preemption. Based on the foregoing, demurrer to the complaint is SUSTAINED with leave to amend. Colvig v. RKO General, Inc. (1965) 232 Cal.App.2d 56, 69–70 [noting the “well-established rule that, even where the defect is one of substance, a demurrer should not be sustained without leave to amend if there is a possibility that subsequent amendments will supply omitted allegations and the plaintiff has not had a fair opportunity to so amend."]. Plaintiff is ordered to file a First Amended Complaint within 30 days.

The parties are reminded that after an amended complaint is filed, "the responding party shall meet and confer again with the party who filed the amended pleading before filing a demurrer to the amended pleading." Code Civ. Proc., § 430.41 subd (a). Defendant shall file a declaration describing the efforts to meet and confer. Id. subd (a)(3).